Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

GABA-containing liposomes: neuroscience applications and translational perspectives for targeting neurological diseases.

Fontes MAP, Vaz GC, Cardoso TZD, de Oliveira MF, Campagnole-Santos MJ, Dos Santos RAS, Sharma NM, Patel KP, Frézard F.

Nanomedicine. 2018 Apr;14(3):781-788. doi: 10.1016/j.nano.2017.12.007. Epub 2017 Dec 24. Review.

2.

Cardiovascular and behavioral effects produced by administration of liposome-entrapped GABA into the rat central nervous system.

Vaz GC, Bahia AP, de Figueiredo Müller-Ribeiro FC, Xavier CH, Patel KP, Santos RA, Moreira FA, Frézard F, Fontes MA.

Neuroscience. 2015 Jan 29;285:60-9. doi: 10.1016/j.neuroscience.2014.10.067. Epub 2014 Nov 13.

PMID:
25446344
3.

Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells.

Vaz GC, Sharma NM, Zheng H, Zimmerman MC, Santos RS, Frezard F, Fontes MAP, Patel KP.

J Neurosci Methods. 2016 Nov 1;273:55-63. doi: 10.1016/j.jneumeth.2016.08.004. Epub 2016 Aug 11.

4.

Liposomes and nanotechnology in drug development: focus on neurological targets.

Ramos-Cabrer P, Campos F.

Int J Nanomedicine. 2013;8:951-60. doi: 10.2147/IJN.S30721. Epub 2013 Mar 3. Review.

5.

A role of GABA analogues in the treatment of neurological diseases.

Gajcy K, Lochyński S, Librowski T.

Curr Med Chem. 2010;17(22):2338-47. Review.

PMID:
20491640
6.

Challenges in development of targeted liposomal therapeutics.

Sawant RR, Torchilin VP.

AAPS J. 2012 Jun;14(2):303-15. doi: 10.1208/s12248-012-9330-0. Epub 2012 Mar 14. Review.

7.

Clodronate liposomes: perspectives in research and therapeutics.

van Rooijen N, van Kesteren-Hendrikx E.

J Liposome Res. 2002 Feb-May;12(1-2):81-94. Review.

PMID:
12604042
8.

[Suppressive effect of GABA-containing liposomes on kindled convulsion].

Mori N, Terayama K, Sato T, Kumashiro H.

No To Shinkei. 1989 Feb;41(2):193-8. Japanese.

PMID:
2736150
9.

Surface functionalizing of a lipid nanosystem to promote brain targeting: step-by-step design and physico-chemical characterization.

Cózar-Bernal MJ, García-Esteban E, Sánchez-Soto PJ, Rabasco AM, González-Rodríguez ML.

Pharm Dev Technol. 2016 Nov;21(7):823-831. Epub 2015 Jul 2.

PMID:
26135385
10.

Natural terpenoids as a promising source for modulation of GABAergic system and treatment of neurological diseases.

Manayi A, Nabavi SM, Daglia M, Jafari S.

Pharmacol Rep. 2016 Aug;68(4):671-9. doi: 10.1016/j.pharep.2016.03.014. Epub 2016 Apr 8. Review.

PMID:
27110875
11.

GABA, gamma-hydroxybutyric acid, and neurological disease.

Wong CG, Bottiglieri T, Snead OC 3rd.

Ann Neurol. 2003;54 Suppl 6:S3-12. Review.

PMID:
12891648
12.

The complexity of the GABAA receptor shapes unique pharmacological profiles.

D'Hulst C, Atack JR, Kooy RF.

Drug Discov Today. 2009 Sep;14(17-18):866-75. doi: 10.1016/j.drudis.2009.06.009. Epub 2009 Jul 2. Review.

PMID:
19576998
13.

Liposomal drug delivery systems: from concept to clinical applications.

Allen TM, Cullis PR.

Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. Review.

PMID:
23036225
14.

Drug delivery to the nervous system.

Maysinger D, Morinville A.

Trends Biotechnol. 1997 Oct;15(10):410-8. Review.

PMID:
9351285
15.

Liposomal drug delivery: a versatile platform for challenging clinical applications.

Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, Tahir N, Ijaz S, Al-Kassas R, Löbenberg R.

J Pharm Pharm Sci. 2014;17(3):401-26. Review.

16.

Immunological GABAergic interactions and therapeutic applications in autoimmune diseases.

Prud'homme GJ, Glinka Y, Wang Q.

Autoimmun Rev. 2015 Nov;14(11):1048-56. doi: 10.1016/j.autrev.2015.07.011. Epub 2015 Jul 29. Review.

PMID:
26226414
17.

Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer.

Gurudevan S, Kanwar RK, Veedu RN, Sasidharan S, Kennedy RL, Walder K, Prasad N, Kanwar JR.

Curr Gene Ther. 2013 Oct;13(5):322-34. Review.

PMID:
24369059
18.

Ligation strategies for targeting liposomal nanocarriers.

Marqués-Gallego P, de Kroon AI.

Biomed Res Int. 2014;2014:129458. doi: 10.1155/2014/129458. Epub 2014 Jul 14. Review.

19.

Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery.

Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, Case AJ, Kottke-Marchant K, Anderson JM, Marchant RE.

J Control Release. 2002 Jan 17;78(1-3):235-47.

PMID:
11772464
20.

Elastic liposomes as novel carriers: recent advances in drug delivery.

Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A.

Int J Nanomedicine. 2017 Jul 17;12:5087-5108. doi: 10.2147/IJN.S138267. eCollection 2017. Review.

Supplemental Content

Support Center